Shots:

• Bausch Health spin-off its leading eye health business into an independent publicly-traded company under the name Bausch + Lomb. The spinoff is expected to be completed in H1’21
• The spinoff will lead to the formation of two separate companies that include an eye-health company built on the iconic Bausch + Lomb brand and a diversified company with leading positions in gastroenterology- aesthetics/dermatology- neurology- and international pharmaceuticals
• Bausch + Lomb will consist of Bausch Health's global vision care- surgical- consumer and ophthalmic Rx businesses which had generated $3.7B revenue in 2019. The other company would comprise brands across the Salix- International Rx- neurology and medical dermatology businesses that generated a revenue pf ~$4.9B in 2019

­ Ref: Bausch Health | Image: Pinterest